The efficacy and safety of Fufangdanshen tablets (Radix Salviae miltiorrhizae formula tablets) for mild to moderate vascular dementia: A study protocol for a randomized controlled trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Tian, Jinzhou ^a   Shi, Jing ^a   Wei, Mingqing ^a   Qin, Renan ^b   Ni, Jingnian ^a   Zhang, Xuekai ^a   Li, Ting ^a   Wang, Yongyan ^c  

^a Dongzhimen Hospital of Beijing University of Chinese Medicine   (China)

^b Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co Ltd   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Chinese medicine; Fufangdanshen tablets; Randomized controlled trial; Vascular dementia

Indexed keywords

CHINESE DRUG; FUFANGDANSHEN; PLACEBO; UNCLASSIFIED DRUG; FUFANG DANSHEN; HERBACEOUS AGENT;

ACTIVITY OF DAILY LIVING ASSESSMENT; ADULT; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL PROTOCOL; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE; CONTROLLED STUDY; DEMENTIA ASSESSMENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; PARALLEL DESIGN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; AGED; CLINICAL TRIAL; DAILY LIFE ACTIVITY; MEDICATION COMPLIANCE; MIDDLE AGED; TABLET; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; CLINICAL PROTOCOLS; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TABLETS;

EID: 84973320131     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1410-5     Document Type: Article

References (28)

1. Dubois MF, Herbert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology. 2001;20:179-87.
2. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54 suppl 5:4-9.
3. Dong MJ, Peng B, Lin XT, Zhao J, Zhou YR, Wang RH. The prevalence of dementia in the People's Republic of China: a systematic analysis of 1980-2004 studies. Age Ageing. 2007;36:619-24.
4. Broich K. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. Internat Psychogeriatrics. 2007;19(3):509-24.
5. Li LX, Ru LQ. Influence of tanshinone on learning and memory impairment induced by amyloidβ-peptide1-40 in rats. Chin J Gerontology. 2003;23:294-7. Article in Chinese.
6. Jiang P, Chen M, Lv J, Chen C, Jiao BH. Effect of tanshinoneIIA on MMP-2 and iNOS expression and free radical release in hippocampus of rat Alzheimer's disease mode. Academic J Second Military Med Univ. 2010;31:380-4. Article in Chinese.
7. Zhu YL, Yang WQ. Effects of Compound Tablet of Red Sage Root on the expression of VEGF in brain of rat during chronic cerebral ischemia. Chin J Practical Nervous Diseases. 2007;10:26-7. Article in Chinese.
8. Wang NS, Liang MR, Liu QD, et al. An experimental study on the effects of borneol as adjuvant drug and messenger drug. J Traditional Chin Med. 1994;35:46-7. Article in Chinese.
9. Zhao LG, Fang TH, Yuan DP. Effects of Fufang Danshen Tablets on the disturbance in learning and memorizing of vascular dementia mice. Lishizhen Medicine Materia Medical Res. 2006;17:959-60. Article in Chinese.
10. Zhang Y, Lin Q, Tang MK, Xu QP, Sun JN. Effects of Fufangdanshen on cholineacetyl transferase and acetylcholinesterase activities of hippocampus and cerebral cortex in rats with senile dementia. J Beijing Univ Traditional Chin Med. 2008;31:192-5. Article in Chinese.
11. Qin RA, Luo JB, Chen M, Huang ZY, Wang H, Yang DS, et al. Effect of Compound Danshen Tablets on amino acid neurotransmitters in brain of Alzheimer's disease rats. Chin Traditional Herbal Drugs. 2004;35:905-7. Article in Chinese.
12. Zhang XY, Qin X, Zhang YF, Lin J, Wang DQ, Qin RA. Protective effects of Compound Danshen Tablets on rat with vascular dementia caused by ischemia and reperfusion in middle cerebral artery. Pharmacol Clin Chin Materia Medica. 2015;01:177-80. Article in Chinese.
13. Folstein M, Folstein S, McHugh P. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189-98.
14. 14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revised. Washington, DC: American Psychiatric Association; 2000
15. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurol. 1993;43:250-60.
16. Rosen W, Terry R. Pathological verification of ischemic score differentiation of dementias. Ann Neurol. 1980;7:486-8.
17. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group Neurol. 1998;50:136-45.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-86.
20. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-64.
21. Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, et al. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11 suppl 3:8-18.
22. Cai YQ, Yang X. The adverse events of the DiAoXinXueKang and FuFangDanShen tablets. Shan Dong J Traditional Chin Med. 2005;24:372-4.
23. Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke. 1996;27:30-6.
24. Gold G, Giannakopoulos P, Montes-Paixao Júnior C, Herrmann FR, Mulligan R, Michel JP, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurol. 1997;49:690-4.
25. Rockwood K, Davis H, MacKnight C, Vandorpe R, Gauthier S, Guzman A. The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. Can J Neurol Sci. 2003;30:237-43.
26. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Medicinal Products for the Treatment of Alzheimer's disease and Other Dementias. London: EMA; accessed in 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003562.pdf.
27. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G, European Task Force Group. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008;7:436-50.
28. Leber P. Guidelines for the clinical evaluation of anti-dementia drugs. Washington, DC: Food & Drug Administration; 1990.